Latest News
Through joint investments by the Swedish government, the Knut and Alice Wallenberg foundation and Astra Zeneca, the Sweden Science for Life Laboratory (SciLifeLab) is to be established as Sweden's new national research institute.
>> Read more
Swedish Albireo AB announces an agreement providing Ajinomoto Pharmaceuticals Ltd exclusive rights to develop and commercialize elobixibat in Japan, South Korea, Indonesia, Thailand, Taiwan and Vietnam.
>> Read more
AstraZeneca and Amgen announce the agreement to jointly develop and commercialize five monoclonal antibodies from Amgen’s clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).
>> Read more
The genomics organization BGI and Danish Novo Nordisk announce the agreement to establish a global collaboration framework. Under the agreement, the collaboration will combine BGI’s next generation sequencing platforms and bioinformatics capabilities with Novo Nordisk’s experience in drug development under a global framework.
>> Read more
The Swedish research company Probi has signed a distribution agreement with the Indian Pharmaceutical company USV Limited. USV will launch Vibact IBS based on the probiotic formulation Probi Digestis later this year in the Indian market.
>> Read more
On March 21, Denmark’s new National Biobank opened in Copenhagen. With more than 15 million biosamples, the unique register will make it possible for researchers to study the Danish population from the cradle to the grave.
>> Read more
The American startup companies FMI Medical Systems and Fluence Therapeutics are establishing R&D centers in Finland, via the BioFinland Technology Bridge Program between the city of Akron (Ohio) and Helsinki.
>> Read more
Uppsala BIO and GöteborgBIO are to cooperate on BIO-X, a structured process for open innovation developed by Uppsala BIO. BIO-X will then be accessible to researchers in the Swedish Västra Götaland region. The cooperation aims to facilitate the collaboration between academic research and small as well as large life science companies.
>> Read more
Heraeus acquires Swedish Biomain AB
On March 1, the Heraeus Dental business group, part of the Hanau-based Heraeus Precious Metals and Technology Group, acquired Swedish Biomain AB. Founded in 2002, and located in Helsingborg, Biomain AB is a leader in the field of custom CAD/CAM-produced implant prosthetics and has a workforce of 40 employees.
>> Read more
In December 2011, the Swedish Data Inspection Board stopped the processing of data in the LifeGene project, arguing that the gathering of personal information for future research contravened the Swedish Personal Data Act. But on February 28, Minister for Education Jan Björklund, presented new rules allowing the LifeGene project to continue.
>> Read more
Sweden is about to get its first trade organization for contract research organizations, sometime during the first half year of 2012. Peter Asplund, responsible for clinical trials at Quintiles in Sweden and Norway, will be president of the new trade organization which will be open to both Swedish companies and other CROs at the Swedish market.
>>Read more
On February 13th, the Disciplinary Committee of NASDAQ OMX Stockholm issued a warning to Active Biotech AB. This is due to the disclosure of information regarding a publication of a press release concerning a Phase III study of the unregistered MS-drug laquinimod.
>>Read more
In the beginning of February, AstraZeneca announced that the research and development operations at the unit in Södertälje will be cancelled, due to reorganization of the research within neuroscience.
>>Read more
The pharmaceutical company Karo Bio has decided to break off the development project for cholesterol lowerer eprotirome. The compound had previously been tested in an animal study and a follow-up now shows that long-term exposure gives unwanted effects. More exactly, damage to cartilage was seen in dogs given eprotirome for up to 12 months and since the company cannot exclude that humans wouldn’t have similar damages, the study is now being terminated.
>>Read more
The Swedish Innovation house Serendipity Innovations has, together with Encubator, the Chalmers University of Technology incubator, commercialized a project which goes by the name of Premune. The project started back in 2009 as part of the educational programs at Chalmers and Sahlgrenska Academy. As part of the business enterprise programs at the universities, students have pursued research ideas provided by industry and academia during the project.
>>Read more
More entries..
![lind441_banner_eng_230x170_fallback[3]](res/default/lind441_banner_eng_230x170_fallback3.gif "lind441_banner_eng_230x170_fallback[3]")
